Hi,
moomoo ID:NaN
Log Out
ENGLISH
  • ENGLISH
  • 中文繁体
  • 中文简体
donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > GMAB Genmab > Detailed Quotes

GMAB Genmab

32.130
+0.200+0.63%
Close 09/30 16:00 ET
32.1300.0000.00%
Post Mkt Price 09/30 16:00 ET
High
32.560
Open
31.860
Turnover
25.82M
Low
31.860
Pre Close
31.930
Volume
802.64K
Market Cap
21.15B
P/E(TTM)
38.02
52wk High
47.280
Shares
658.29M
P/E(Static)
46.16
52wk Low
26.190
Float Cap
20.84B
Bid/Ask %
0.00%
Historical High
49.070
Shs Float
648.76M
Volume Ratio
1.07
Historical Low
16.240
Dividend TTM
--
Div Yield TTM
--
P/B
6.09
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.12%
Amplitude
2.19%
Avg Price
32.163
Lot Size
1
Float Cap
20.84B
Bid/Ask %
0.00%
Historical High
49.070
Shs Float
648.76M
Volume Ratio
1.07
Historical Low
16.240
Dividend TTM
--
P/B
6.09
Dividend LFY
--
Turnover Ratio
0.12%
Amplitude
2.19%
Avg Price
32.163
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
Genmab A/S operates as an international biotechnology company. The firm develops human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline include daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998 and is headquartered in Copenhagen, Denmark.
CEO: Dr. Jan G. J. van de Winkel, PhD
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...